Pharmaceutical preparation containing copolyvidone

a technology of copolyvidone and pharmaceutical preparation, which is applied in the directions of organic chemistry, coatings, and active ingredients of heterocyclic compounds, can solve the problem of insufficient activity and achieve the effect of improving plasticity and film strength

Inactive Publication Date: 2004-01-29
TAKEDA PHARMA CO LTD
View PDF7 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0003] Tablets essentially require the addition of plasticizers in order to increase the film strength and to improve the plast...

Problems solved by technology

However, depending on an active compound such as a pharmaceutically active ingredient, the stability of a base drug to heat or light is impaired by the addition of polyethy...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation containing copolyvidone
  • Pharmaceutical preparation containing copolyvidone
  • Pharmaceutical preparation containing copolyvidone

Examples

Experimental program
Comparison scheme
Effect test

reference example 2

Synthesis of Ethyl (E)-3-(2,3-Dihydrobenzofuran-5-yl)propenoate

[0336] To 2,3-dihydrobenzofuran-5-carbaldehyde obtained Reference Example 1 (832.3 mmol) / toluene solution (340 g), triethyl phosphonoacetate (205.3 g, 915.7 mmol) was added dropwise under cooling. Then, t-butoxy sodium (88.0 g, 1187.3 mmol) suspended in toluene (530 g) was added dropwise to the resultant mixture and, after stirring the mixture for one hour, acetic acid (20 g) and water (500 g) were further added dropwise thereto. The reaction mixture was raised to room temperature and partitioned. The organic layer was washed in turn with saturated sodium bicarbonate water and water and concentrated under reduced pressure until the volume is reduced to 300 mL or less. Methanol (396 g) was added and the mixture was heated to dissolve it. Water (500 g) was added dropwise thereto at room temperature and the mixture was stirred to deposit crystals. The crystals were collected by filtration and dried under reduced pressure to...

reference example 3

Synthesis of Ethyl 3-(2,3-Dihydrobenzofuran-5-yl)propionate

[0337] Ethyl (E)-3-(2,3-dihydrobenzofuran-5-yl)propionate (50.0 g, 227.3 mmol) was dissolved in acetic acid (312.0 g). After replacing the atmosphere in the system with nitrogen, 5% Pd / C (4.96 g) (as dry) was added to the solution and the system was pressurized with hydrogen up to 196 to 294 kPa. The reaction was conducted at 50.degree. C. under pressure of 196 to 294 kPa for one hour. The catalyst was removed by filtration, and then the reaction mixture was washed with acetic acid (208 g) to obtain an acetic acid solution of the title compound (yield: 569.3 g, apparent yield: 100%).

reference example 4

Synthesis of 3-(6,7-Dibromo-2,3-dihydrobenzofuran-5-yl)propionic Acid

[0338] To the PPE / acetic acid solution (569.3 g, 227.3 mmol) obtained from the process of Reference Example 3, anhydrous sodium acetate (18.6 g) was added. Bromine (221.6 g) was added dropwise to the resultant mixture over 2 hours under cooling with stirring. Then, the reaction was conducted at room temperature for 4 hours and the reaction mixture was added dropwise to a cooled aqueous 15% sodium sulfite solution (670 ml), followed by stirring for 30 minutes. Acetonitrile (118 g) was added thereto and the mixture was reacted by heating under reflux for 2 hours. The mixture was gradually cooled and stirred for one hour to deposit crystals. The crystals were collected by filtration, washed with water and then dried to obtain the title compound (yield: 63.3 g, 73.2%).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

Description

[0001] The present invention relates to a preparation, particularly a pharmaceutical preparation which is coated with a coating agent containing copolyvidone and is superior in storage stability, and the like.[0002] Tablets used commonly as oral preparations are formed by using various additives such as diluents, binders, lubricants, disintegrators, etc. Depending on an active compound, some tablets are less stable to light during circulation and storage and these tablets are often provided with a coating film capable of exerting a light protecting effect by film coating. It is also a useful means to form a coating film in order to prevent bitterness of a drug. This coating film is generally composed of hydroxypropylmethylcellulose (HPMC) or hydroxypropylcellulose (HPC) as water-soluble coating film agents, polyethylene glycol (PEG) as plasticizers and titanium dioxide as light-protecting agents and, if necessary, iron sesquioxide such as colorants.OBJECTS OF THE INVENTION[0003] Tab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/28A61K9/32A61K9/36A61K31/137A61K31/343A61K31/352A61K31/36A61K31/407A61K47/32C07D307/93C07D491/048C07D491/052
CPCA61K9/284A61K9/2866A61K31/137A61K31/343C07D307/93A61K31/36A61K31/407A61K47/32A61K31/352A61K9/2813
Inventor ISHIDA, HAJIMEFUKUTA, MAKOTO
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap